S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The single greatest medical breakthrough of all time? (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
The single greatest medical breakthrough of all time? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The single greatest medical breakthrough of all time? (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
The single greatest medical breakthrough of all time? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The single greatest medical breakthrough of all time? (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
The single greatest medical breakthrough of all time? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The single greatest medical breakthrough of all time? (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
The single greatest medical breakthrough of all time? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

$0.58
-0.02 (-3.34%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.56
$0.66
50-Day Range
$0.58
$1.14
52-Week Range
$0.55
$4.86
Volume
2.48 million shs
Average Volume
224,603 shs
Market Capitalization
$9.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
763.6% Upside
$5.00 Price Target
Short Interest
Healthy
4.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
-0.25mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$11,131 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars


ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

ACRX Price History

ACRX Stock News Headlines

AcelRx CEO buys 10,000 shares
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Positive Report for Acelrx (ACRX) from H.C. Wainwright
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call
ACRX - AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals (NASDAQ: ACRX)
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+763.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$47.76 million
Net Margins
2,696.50%
Pretax Margin
-2,598.42%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share

Miscellaneous

Free Float
15,850,000
Market Cap
$9.46 million
Optionable
Optionable
Beta
0.23
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Vincent J. Angotti (Age 55)
    CEO & Director
    Comp: $906.54k
  • Dr. Pamela Pierce Palmer M.D. (Age 60)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $699.75k
  • Mr. Raffi Mark Asadorian (Age 54)
    Chief Financial Officer
    Comp: $637.5k
  • Mr. Anil N. Dasu (Age 60)
    Chief Engineering Officer













ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings
or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price forecast for 2023?

1 brokers have issued 12 month price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 763.6% from the stock's current price.
View analysts price targets for ACRX
or view top-rated stocks among Wall Street analysts.

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 74.4% and is now trading at $0.5790.
View the best growth stocks for 2023 here
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings results on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.12. The specialty pharmaceutical company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.08 million. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 100.94%.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Values First Advisors Inc. (1.12%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.58.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $9.46 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or ($3.09) on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -